Everything we've seen

1. ?Sep 14, 3:20 PMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

2. !Sep 14, 3:20 PMsignalseverity 0.20

   Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

   PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

3. ?Sep 14, 3:20 PMdecisionconsidered

   Agent 5 — Dip Buyer (Evolving) — decide: skip

   PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

4. !Sep 14, 3:20 PMsignalseverity 0.20

   Agent 5 — Dip Buyer (Evolving) — dip_skipped

   PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

5. ?Sep 14, 2:20 PMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

6. !Sep 14, 2:20 PMsignalseverity 0.21

   Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

   PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

7. ?Sep 14, 2:20 PMdecisionconsidered

   Agent 5 — Dip Buyer (Evolving) — decide: skip

   PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

8. !Sep 14, 2:20 PMsignalseverity 0.21

   Agent 5 — Dip Buyer (Evolving) — dip_skipped

   PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

9. ?Sep 14, 1:20 PMdecisionconsidered

   Agent 5 — Dip Buyer (Evolving) — decide: skip

   PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

10. !Sep 14, 1:20 PMsignalseverity 0.21

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

11. ?Sep 14, 1:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

12. !Sep 14, 1:20 PMsignalseverity 0.21

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

13. ?Sep 14, 12:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

14. !Sep 14, 12:20 PMsignalseverity 0.20

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

15. ?Sep 14, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

16. !Sep 14, 12:20 PMsignalseverity 0.20

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

17. ?Sep 14, 11:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

18. !Sep 14, 11:21 AMsignalseverity 0.21

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

19. ?Sep 14, 11:21 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

20. !Sep 14, 11:21 AMsignalseverity 0.21

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

21. ?Sep 14, 10:21 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

22. !Sep 14, 10:21 AMsignalseverity 0.23

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

23. ?Sep 14, 10:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

24. !Sep 14, 10:21 AMsignalseverity 0.23

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

25. ?Sep 14, 7:01 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

26. !Sep 14, 7:01 AMsignalseverity 0.23

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

27. ?Sep 14, 7:00 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

28. !Sep 14, 7:00 AMsignalseverity 0.23

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

29. ?Sep 11, 6:04 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medtech company in the insulin delivery space with a strong product portfolio (OmniPod), and no news headlines or SEC filings in the window indicate company-specific deterioration such as guidance cuts, accounting issues, or competitive collapse. The 10-Q and 8-K filings lack extractable metrics, making it difficult to confirm recent financial trends, but the absence of negative catalysts in the news is somewhat reassuring. However, the macro backdrop presents a headwind: the 5-year forward inflation rate is 1.8σ above its 24-month trend, suggesting elevated rate sensitivity that could weigh on growth-oriented medtech names like PODD, which typically trade at premium multiples.

30. !Sep 11, 6:04 PMsignalseverity 0.23

    Agent 4 — Dip Buyer (Frozen) — dip_skipped

    PODD (Insulet Corporation) is a fundamentally sound medtech company in the insulin delivery space with a strong product portfolio (OmniPod), and no news headlines or SEC filings in the window indicate company-specific deterioration such as guidance cuts, accounting issues, or competitive collapse. The 10-Q and 8-K filings lack extractable metrics, making it difficult to confirm recent financial trends, but the absence of negative catalysts in the news is somewhat reassuring. However, the macro backdrop presents a headwind: the 5-year forward inflation rate is 1.8σ above its 24-month trend, suggesting elevated rate sensitivity that could weigh on growth-oriented medtech names like PODD, which typically trade at premium multiples.

31. ?Sep 11, 4:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

32. !Sep 11, 4:20 PMsignalseverity 0.23

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

33. ?Sep 11, 4:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

34. !Sep 11, 4:20 PMsignalseverity 0.23

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

35. ?Sep 11, 3:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

36. !Sep 11, 3:20 PMsignalseverity 0.23

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

37. ?Sep 11, 3:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

38. !Sep 11, 3:20 PMsignalseverity 0.23

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

39. ?Sep 11, 2:21 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

40. !Sep 11, 2:21 PMsignalseverity 0.23

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

41. ?Sep 11, 2:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

42. !Sep 11, 2:21 PMsignalseverity 0.23

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

43. ?Sep 11, 1:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

44. !Sep 11, 1:20 PMsignalseverity 0.23

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

45. ?Sep 11, 1:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

46. !Sep 11, 1:20 PMsignalseverity 0.23

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

47. ?Sep 11, 12:21 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

48. !Sep 11, 12:21 PMsignalseverity 0.23

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

49. ?Sep 11, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

50. !Sep 11, 12:20 PMsignalseverity 0.23

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    PODD is down 23.1% from its 30-day high — a significant drawdown that would normally qualify as a mean-reversion candidate (+1). However, the signal stack is thin: no insider buying, no options flow data, no news headlines, and no financial metrics in the filings to confirm fundamental soundness. The Health Care sector is underperforming SPY on both 5d and 30d bases (+1 for sector-wide weakness rather than idiosyncratic), and today's broad market is mildly positive. Against these positives, the 10Y yield at 4.83% is a structural headwind for a growth-oriented medtech name like PODD (-1), and earnings are 54 days away — not a veto but adding uncertainty. Net signal score is approximately +1, which is marginal and does not clear the bar for a buy without a strong insider or options catalyst.

51. ·Sep 11, 9:46 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

52. ·Sep 11, 9:31 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

53. ·Sep 11, 9:16 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

54. ·Sep 11, 9:00 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

55. ·Sep 11, 8:45 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

56. ·Sep 11, 8:30 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

57. ·Sep 11, 8:15 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

58. ·Sep 11, 8:00 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

59. ·Sep 11, 7:45 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

60. ·Sep 11, 7:30 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

61. ·Sep 11, 7:15 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

62. ·Sep 11, 7:00 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

63. ·Sep 11, 6:45 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

64. ·Sep 11, 6:30 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

65. ·Sep 11, 6:15 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

66. ·Sep 11, 6:00 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

67. ·Sep 11, 5:45 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

68. ·Sep 11, 5:30 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

69. ·Sep 11, 5:15 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

70. ·Sep 11, 5:00 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

71. ·Sep 11, 4:45 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

72. ·Sep 11, 4:30 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

73. ·Sep 11, 4:15 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

74. ·Sep 11, 4:00 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

75. ·Sep 11, 3:45 AMstreamnews

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

76. ▣Sep 10, 8:00 PMjournalstop

    Agent 5 — Dip Buyer (Evolving) closed long 11 @ $133.63 (-$138.65)

    intraday stop sweep

77. ?Sep 10, 4:26 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

78. !Sep 10, 4:26 PMsignalseverity 0.22

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

79. ?Sep 10, 2:50 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    PODD is down 2.69% with 55 minutes remaining, a meaningful move suggesting real institutional flow. However, several factors temper continuation confidence. The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend — this is modestly negative for rate-sensitive growth/medtech names like PODD, providing a mild tailwind for the downside thesis. However, with no news catalyst identified, the move may reflect broader sector rotation rather than stock-specific conviction, making it harder to assess whether sellers have more to do. The 55-minute window is narrow — most of the day's move is already in, and without a clear continuation catalyst, mean-reversion pressure into the close is plausible as intraday traders lock in short profits. PODD is a relatively illiquid name compared to mega-cap, and without volume confirmation data, I cannot rule out a thin-market exaggerated move that partially reverses. The time remaining and absence of a clear catalyst push this just below the 0.5 threshold — the risk/reward of fading momentum this late without a strong directional reason is not compelling enough to trigger.

80. !Sep 10, 2:50 PMsignalseverity -0.03

    Agent 7 — Day Trader — day_trade_skipped

    PODD is down 2.69% with 55 minutes remaining, a meaningful move suggesting real institutional flow. However, several factors temper continuation confidence. The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend — this is modestly negative for rate-sensitive growth/medtech names like PODD, providing a mild tailwind for the downside thesis. However, with no news catalyst identified, the move may reflect broader sector rotation rather than stock-specific conviction, making it harder to assess whether sellers have more to do. The 55-minute window is narrow — most of the day's move is already in, and without a clear continuation catalyst, mean-reversion pressure into the close is plausible as intraday traders lock in short profits. PODD is a relatively illiquid name compared to mega-cap, and without volume confirmation data, I cannot rule out a thin-market exaggerated move that partially reverses. The time remaining and absence of a clear catalyst push this just below the 0.5 threshold — the risk/reward of fading momentum this late without a strong directional reason is not compelling enough to trigger.

81. ?Sep 10, 12:40 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    PODD is down 1.65% today, which is a moderate but not exceptional move. No headlines to explain the move or suggest a catalyst driving sustained selling pressure. The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend — this is modestly bearish for rate-sensitive and growth-oriented medtech names like PODD (an insulin pump/CGM device company with a high valuation multiple), which could lend mild tail wind to the downside. However, at 185 minutes remaining there is still meaningful time, but the move is not large enough to signal strong institutional conviction on its own. Without a clear catalyst and with the macro pressure being a general headwind rather than a PODD-specific driver, there is insufficient evidence of strong continuation momentum. The 1.65% decline is within normal daily volatility range for this ticker and could easily mean-revert into the close on light afternoon flows. No reversal pattern is visible, but no strong continuation signal either. Probability sits just below the 0.5 threshold — marginally favoring a fade or sideways rather than continued selloff.

82. !Sep 10, 12:40 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    PODD is down 1.65% today, which is a moderate but not exceptional move. No headlines to explain the move or suggest a catalyst driving sustained selling pressure. The macro context shows 5-year forward inflation expectations elevated at 1.6σ above trend — this is modestly bearish for rate-sensitive and growth-oriented medtech names like PODD (an insulin pump/CGM device company with a high valuation multiple), which could lend mild tail wind to the downside. However, at 185 minutes remaining there is still meaningful time, but the move is not large enough to signal strong institutional conviction on its own. Without a clear catalyst and with the macro pressure being a general headwind rather than a PODD-specific driver, there is insufficient evidence of strong continuation momentum. The 1.65% decline is within normal daily volatility range for this ticker and could easily mean-revert into the close on light afternoon flows. No reversal pattern is visible, but no strong continuation signal either. Probability sits just below the 0.5 threshold — marginally favoring a fade or sideways rather than continued selloff.

83. ?Sep 10, 11:00 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    PODD is down ~2% with no attributable headline, suggesting either broad sector/macro pressure or quiet institutional flow. The macro context shows the 5Y5Y forward inflation rate (T5YIFR) printing 1.6σ above trend, which creates a headwind for rate-sensitive sectors and growth/medical device names like PODD that carry premium valuations and are sensitive to discount rate assumptions. This macro backdrop is modestly supportive of continued downside pressure. However, the move is at the low end of the 2-5% 'meaningful conviction' range, no news catalyst is present to sustain narrative-driven selling, and with 285 minutes remaining (roughly 4.75 hours — essentially the full remaining session), there is ample time for either continuation or reversal. The absence of a catalyst means this could be slow bleed or could simply fade as sellers exhaust. No reversal pattern is visible from the data provided. On balance, a slight lean toward continuation given the macro rate headwind on a growth medical device name, but conviction is modest. Probability lands at the threshold floor given the weak signal strength.

84. !Sep 10, 11:00 AMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    PODD is down ~2% with no attributable headline, suggesting either broad sector/macro pressure or quiet institutional flow. The macro context shows the 5Y5Y forward inflation rate (T5YIFR) printing 1.6σ above trend, which creates a headwind for rate-sensitive sectors and growth/medical device names like PODD that carry premium valuations and are sensitive to discount rate assumptions. This macro backdrop is modestly supportive of continued downside pressure. However, the move is at the low end of the 2-5% 'meaningful conviction' range, no news catalyst is present to sustain narrative-driven selling, and with 285 minutes remaining (roughly 4.75 hours — essentially the full remaining session), there is ample time for either continuation or reversal. The absence of a catalyst means this could be slow bleed or could simply fade as sellers exhaust. No reversal pattern is visible from the data provided. On balance, a slight lean toward continuation given the macro rate headwind on a growth medical device name, but conviction is modest. Probability lands at the threshold floor given the weak signal strength.

85. ?Sep 9, 4:25 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

86. !Sep 9, 4:25 PMsignalseverity 0.20

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the ~20% drop — no headlines, no earnings miss, and no insider selling. The drop appears macro/sector-driven, as Health Care (XLV) is underperforming SPY on both 5d and 30d basis, and today's broad market tone is risk-off (VIX elevated, small caps down ~1.35%). However, the evidence for a large rebound is thin: no insider cluster buys, no unusual call flow, no analyst upgrades post-drop, and sparse SEC filings with empty metrics. Earnings are 56 days away (non-factor), and VIX is low (17th percentile), suggesting the macro environment is not panic-driven.

87. ❖Sep 9, 1:27 PMnewsvia finnhub

    Insulet Corporation (PODD) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

    Insulet Corporation (PODD) Wells Fargo 21st Annual Healthcare Conference September 9, 2026 2:15 PM EDTCompany ParticipantsAshley McEvoy - CEO, President...

88. ?Sep 9, 9:40 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    PODD is down 1.82% with no attributable headline catalyst, suggesting this is likely flow-driven or macro-sensitive selling. The macro context shows T5YIFR elevated at 1.8σ above trend — elevated forward inflation expectations tend to pressure growth/medical device names like PODD through a higher discount rate channel, providing a mild tailwind for continued selling. However, the move is only 1.82%, which is below the 2-5% threshold where momentum conviction is strongest. With 365 minutes remaining (essentially a full trading day remains — this appears to be an early session read), there is ample time for the move to either continue or reverse. No news is present, which is neutral per guidance. The macro headwind is real but modest. The move size is sub-threshold for strong continuation signals. Overall, conditions modestly favor continuation given the rate-sensitive macro backdrop pressing on this sector, but conviction is low — assigning 0.50 as a borderline call where the system's bounded risk profile justifies taking the position.

89. ?Sep 8, 4:22 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medtech company in the insulin delivery space with a strong market position, and an 18.7% drop is meaningful but not catastrophic. However, the evidence base is extremely thin: no news headlines explain the drop, the 10-Q and 8-K filings contain no readable metrics, there is no insider buying, no options flow confirmation, and no sector-specific negative catalyst (Health Care is actually outperforming SPY on both 5d and 30d basis). The fact that the sector is outperforming while PODD is down sharply suggests idiosyncratic risk — an unconfirmed negative catalyst — which is a cautionary signal without a recovery thesis. Earnings are 57 days away (non-factor), VIX is very low at 14.32, and the 10Y at 4.77% is a mild structural headwind for growth medtech. Without confirmation signals or a clear overreaction narrative, the setup lacks the asymmetry profile needed for a high-conviction buy.

90. ?Sep 8, 1:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medtech company in the insulin delivery space with a strong market position, and an 18.7% drop is meaningful but not catastrophic. However, the evidence base is extremely thin: no news headlines explain the drop, the 10-Q and 8-K filings contain no readable metrics, there is no insider buying, no options flow confirmation, and no sector-specific negative catalyst (Health Care is actually outperforming SPY on both 5d and 30d basis). The fact that the sector is outperforming while PODD is down sharply suggests idiosyncratic risk — an unconfirmed negative catalyst — which is a cautionary signal without a recovery thesis. Earnings are 57 days away (non-factor), VIX is very low at 14.32, and the 10Y at 4.77% is a mild structural headwind for growth medtech. Without confirmation signals or a clear overreaction narrative, the setup lacks the asymmetry profile needed for a high-conviction buy.

91. ?Sep 8, 11:25 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medtech company in the insulin delivery space with a strong market position, and an 18.7% drop is meaningful but not catastrophic. However, the evidence base is extremely thin: no news headlines explain the drop, the 10-Q and 8-K filings contain no readable metrics, there is no insider buying, no options flow confirmation, and no sector-specific negative catalyst (Health Care is actually outperforming SPY on both 5d and 30d basis). The fact that the sector is outperforming while PODD is down sharply suggests idiosyncratic risk — an unconfirmed negative catalyst — which is a cautionary signal without a recovery thesis. Earnings are 57 days away (non-factor), VIX is very low at 14.32, and the 10Y at 4.77% is a mild structural headwind for growth medtech. Without confirmation signals or a clear overreaction narrative, the setup lacks the asymmetry profile needed for a high-conviction buy.

92. ?Sep 8, 9:40 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    PODD is down 1.60% today, which is a moderate but not outsized move. No news headlines are available to explain the move or confirm directional conviction. The macro context shows the 5-year forward inflation rate printing 1.7σ above trend, which is a headwind for rate-sensitive and growth-oriented medtech names like PODD — this could provide mild continuation pressure to the downside. However, with 365 minutes remaining (essentially the full afternoon session), there is ample time for mean reversion as well. The absence of a catalyst makes it harder to assign high continuation probability. The move of -1.60% is below the 2-5% threshold that typically signals strong institutional conviction. Balancing the modest macro headwind against the lack of news-driven catalyst and the elevated probability of intraday fade for sub-2% moves in medtech, I place continuation probability just below the 0.5 trigger threshold. This is a borderline read but the lack of any supporting flow narrative and the elevated inflation rate environment (which could attract defensive rotation rather than sustained selling in a single name) tilts me slightly toward fade rather than continuation.

93. ❖Sep 8, 9:24 AMnewsvia finnhub

    Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?

    PODD's Omnipod 5 adoption, product expansion and raised international growth outlook support its growth prospects despite competitive and cost pressures.

94. ❖Sep 8, 9:00 AMnewsvia finnhub

    Artisan Sold Insulet (PODD) Due to Competition Concerns

    Artisan Partners, an investment management company, released its second-quarter 2026 investor letter for the “Artisan Mid Cap Fund”. The letter can be downloaded here. Global equities rebounded sharply in Q2 2026, recovering from March lows as resilient economic data, strong corporate earnings, and continued AI investment improved investor sentiment despite inflation concerns, delayed rate cuts, and […]

95. ?Sep 4, 7:23 PMdecisionconsidered

    Agent 4 — Dip Buyer (Frozen) — decide: skip

    The recent news headline noting PODD is up 8.1% since the last earnings report suggests the fundamental post-earnings narrative remains positive, and the 14.7% pullback from the 30-day high appears to be a technical/macro-driven retracement rather than company-specific deterioration. However, the macro context is a headwind: the 5-year forward inflation rate is running 1.7σ above trend, which pressures rate-sensitive growth/medtech names like Insulet. The SEC filings (8-K and 10-Q) have no reported metrics to confirm or deny financial health, leaving the assessment reliant on the positive earnings sentiment and absence of negative catalysts. On re-entry context, the stock at $147.48 has recovered above the prior entry of $138.97 but sits well below the stop-out price of $167.37, meaning the recovery is only partial and may reflect general mean reversion rather than a fresh fundamental catalyst warranting confident re-entry.

96. ?Sep 4, 4:23 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the 15.4% drop from its 30-day high. The evidence base is thin — no news headlines, no meaningful metrics in the SEC filings, and no options flow data — leaving the cause of the decline unclear (likely macro/sector rotation). Health Care sector is ranked 4th of 11 by 30-day relative strength with modest underperformance vs SPY (-0.99pts over 30d), suggesting this is partly a sector-wide move rather than idiosyncratic deterioration. Earnings are 72 days away (non-factor), and VIX at the 6th percentile indicates a low-volatility, complacent market — not a panic dip driven by fear.

97. ?Sep 4, 2:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the 15.4% drop from its 30-day high. The evidence base is thin — no news headlines, no meaningful metrics in the SEC filings, and no options flow data — leaving the cause of the decline unclear (likely macro/sector rotation). Health Care sector is ranked 4th of 11 by 30-day relative strength with modest underperformance vs SPY (-0.99pts over 30d), suggesting this is partly a sector-wide move rather than idiosyncratic deterioration. Earnings are 72 days away (non-factor), and VIX at the 6th percentile indicates a low-volatility, complacent market — not a panic dip driven by fear.

98. ?Sep 4, 1:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the 15.4% drop from its 30-day high. The evidence base is thin — no news headlines, no meaningful metrics in the SEC filings, and no options flow data — leaving the cause of the decline unclear (likely macro/sector rotation). Health Care sector is ranked 4th of 11 by 30-day relative strength with modest underperformance vs SPY (-0.99pts over 30d), suggesting this is partly a sector-wide move rather than idiosyncratic deterioration. Earnings are 72 days away (non-factor), and VIX at the 6th percentile indicates a low-volatility, complacent market — not a panic dip driven by fear.

99. ?Sep 4, 12:24 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the 15.4% drop from its 30-day high. The evidence base is thin — no news headlines, no meaningful metrics in the SEC filings, and no options flow data — leaving the cause of the decline unclear (likely macro/sector rotation). Health Care sector is ranked 4th of 11 by 30-day relative strength with modest underperformance vs SPY (-0.99pts over 30d), suggesting this is partly a sector-wide move rather than idiosyncratic deterioration. Earnings are 72 days away (non-factor), and VIX at the 6th percentile indicates a low-volatility, complacent market — not a panic dip driven by fear.

100. ❖Sep 4, 11:30 AMnewsvia finnhub

     Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report?

     Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

101. ❖Sep 4, 7:10 AMnewsvia finnhub

     Baron SMID Cap ETF Q2 2026 Portfolio Activity

     During the quarter, we initiated a position in Advanced Drainage Systems, the leading U.S. manufacturer of stormwater and onsite wastewater management products.

102. ❖Sep 3, 8:39 PMnewsvia finnhub

     Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks

     As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the patient monitoring industry, including Insulet (NASDAQ:PODD) and its peers.

103. ?Sep 3, 4:22 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the 15.4% drop from its 30-day high. The evidence base is thin — no news headlines, no meaningful metrics in the SEC filings, and no options flow data — leaving the cause of the decline unclear (likely macro/sector rotation). Health Care sector is ranked 4th of 11 by 30-day relative strength with modest underperformance vs SPY (-0.99pts over 30d), suggesting this is partly a sector-wide move rather than idiosyncratic deterioration. Earnings are 72 days away (non-factor), and VIX at the 6th percentile indicates a low-volatility, complacent market — not a panic dip driven by fear.

104. ?Sep 3, 3:22 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the 15.4% drop from its 30-day high. The evidence base is thin — no news headlines, no meaningful metrics in the SEC filings, and no options flow data — leaving the cause of the decline unclear (likely macro/sector rotation). Health Care sector is ranked 4th of 11 by 30-day relative strength with modest underperformance vs SPY (-0.99pts over 30d), suggesting this is partly a sector-wide move rather than idiosyncratic deterioration. Earnings are 72 days away (non-factor), and VIX at the 6th percentile indicates a low-volatility, complacent market — not a panic dip driven by fear.

105. ?Sep 3, 1:23 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the 15.4% drop from its 30-day high. The evidence base is thin — no news headlines, no meaningful metrics in the SEC filings, and no options flow data — leaving the cause of the decline unclear (likely macro/sector rotation). Health Care sector is ranked 4th of 11 by 30-day relative strength with modest underperformance vs SPY (-0.99pts over 30d), suggesting this is partly a sector-wide move rather than idiosyncratic deterioration. Earnings are 72 days away (non-factor), and VIX at the 6th percentile indicates a low-volatility, complacent market — not a panic dip driven by fear.

106. ?Sep 3, 11:25 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the 15.4% drop from its 30-day high. The evidence base is thin — no news headlines, no meaningful metrics in the SEC filings, and no options flow data — leaving the cause of the decline unclear (likely macro/sector rotation). Health Care sector is ranked 4th of 11 by 30-day relative strength with modest underperformance vs SPY (-0.99pts over 30d), suggesting this is partly a sector-wide move rather than idiosyncratic deterioration. Earnings are 72 days away (non-factor), and VIX at the 6th percentile indicates a low-volatility, complacent market — not a panic dip driven by fear.

107. ?Sep 2, 4:23 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the 15.4% drop from its 30-day high. The evidence base is thin — no news headlines, no meaningful metrics in the SEC filings, and no options flow data — leaving the cause of the decline unclear (likely macro/sector rotation). Health Care sector is ranked 4th of 11 by 30-day relative strength with modest underperformance vs SPY (-0.99pts over 30d), suggesting this is partly a sector-wide move rather than idiosyncratic deterioration. Earnings are 72 days away (non-factor), and VIX at the 6th percentile indicates a low-volatility, complacent market — not a panic dip driven by fear.

108. ❖Sep 2, 4:11 PMnewsvia finnhub

     Insulet (PODD) Stock May Be 40% Undervalued On Fair Value Grounds

     Insulet stock has fallen sharply over the past year, yet both an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach and market multiples currently point to the shares trading below what those models suggest, while the broader valuation score still comes through as a mixed signal rather than a clear bargain. The share price is down 57.0% over the past year, which puts recent trading well below where many investors may have entered the stock. Future adoption of Insulet's...

109. ?Sep 2, 3:24 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the 15.4% drop from its 30-day high. The evidence base is thin — no news headlines, no meaningful metrics in the SEC filings, and no options flow data — leaving the cause of the decline unclear (likely macro/sector rotation). Health Care sector is ranked 4th of 11 by 30-day relative strength with modest underperformance vs SPY (-0.99pts over 30d), suggesting this is partly a sector-wide move rather than idiosyncratic deterioration. Earnings are 72 days away (non-factor), and VIX at the 6th percentile indicates a low-volatility, complacent market — not a panic dip driven by fear.

110. ❖Sep 2, 11:09 AMnewsvia finnhub

     Is Insulet (PODD) Undervalued On Lawsuit And Device Correction Risks?

     Insulet (PODD) is back in focus after ongoing reminders about a securities class action lawsuit tied to alleged issues in its manufacturing controls and recent voluntary Medical Device Corrections disclosed in March and May 2026. At a share price of US$148.38, Insulet has seen short term resilience with a 7 day share price return of 3.73%. However, the 30 day share price return is down 10.26% and the 1 year total shareholder return has declined 56.98%, which points to fading momentum as...

111. ?Sep 2, 7:06 AMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the 15.4% drop from its 30-day high. The evidence base is thin — no news headlines, no meaningful metrics in the SEC filings, and no options flow data — leaving the cause of the decline unclear (likely macro/sector rotation). Health Care sector is ranked 4th of 11 by 30-day relative strength with modest underperformance vs SPY (-0.99pts over 30d), suggesting this is partly a sector-wide move rather than idiosyncratic deterioration. Earnings are 72 days away (non-factor), and VIX at the 6th percentile indicates a low-volatility, complacent market — not a panic dip driven by fear.

112. ?Sep 1, 4:23 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the 15.4% drop from its 30-day high. The evidence base is thin — no news headlines, no meaningful metrics in the SEC filings, and no options flow data — leaving the cause of the decline unclear (likely macro/sector rotation). Health Care sector is ranked 4th of 11 by 30-day relative strength with modest underperformance vs SPY (-0.99pts over 30d), suggesting this is partly a sector-wide move rather than idiosyncratic deterioration. Earnings are 72 days away (non-factor), and VIX at the 6th percentile indicates a low-volatility, complacent market — not a panic dip driven by fear.

113. ❖Sep 1, 8:47 AMnewsvia finnhub

     MiniMed submits new patch pump for FDA clearance

     The diabetes tech firm is preparing for the launch of new devices, including a tubeless insulin pump and a fully closed loop automated insulin delivery system.

114. ?Aug 31, 4:23 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the 15.4% drop from its 30-day high. The evidence base is thin — no news headlines, no meaningful metrics in the SEC filings, and no options flow data — leaving the cause of the decline unclear (likely macro/sector rotation). Health Care sector is ranked 4th of 11 by 30-day relative strength with modest underperformance vs SPY (-0.99pts over 30d), suggesting this is partly a sector-wide move rather than idiosyncratic deterioration. Earnings are 72 days away (non-factor), and VIX at the 6th percentile indicates a low-volatility, complacent market — not a panic dip driven by fear.

115. ?Aug 31, 3:24 PMdecisionconsidered

     Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

     PODD (Insulet Corporation) is a fundamentally sound medical device company in the insulin delivery space with no confirmed negative catalyst explaining the 15.4% drop from its 30-day high. The evidence base is thin — no news headlines, no meaningful metrics in the SEC filings, and no options flow data — leaving the cause of the decline unclear (likely macro/sector rotation). Health Care sector is ranked 4th of 11 by 30-day relative strength with modest underperformance vs SPY (-0.99pts over 30d), suggesting this is partly a sector-wide move rather than idiosyncratic deterioration. Earnings are 72 days away (non-factor), and VIX at the 6th percentile indicates a low-volatility, complacent market — not a panic dip driven by fear.

116. ❖Aug 31, 12:35 PMnewsvia finnhub

     Uncover the latest developments among S&P500 stocks in today's session.

     Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.

117. ❖Aug 29, 7:30 AMnewsvia finnhub

     Insulet Corporation: Strong Growth Meets A New Execution Problem

     Insulet Corporation delivered strong Q2 2026 results with 23.5% revenue growth, strong customer additions, and solid profitability. Click for more on PODD.

118. ❖Aug 27, 6:00 AMnewsvia finnhub

     Insulet (NASDAQ:PODD): Growth at a Reasonable Valuation

     Insulet Corp (PODD) fits the affordable growth screen: strong EPS and revenue growth, reasonable valuation, and overall solid profitability.

119. ❖Aug 26, 5:36 AMnewsvia finnhub

     FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking

     The FDA authorized Abbott's Libre Duo 10 Day, the first wearable tracking both glucose and ketones continuously for diabetes patients.

120. ❖Aug 24, 7:11 PMnewsvia finnhub

     The Bottom Fishing Club - Embecta: Excellent Turnaround Prospect In Defensive Medical Products

     Embecta (EMBC) looks like a deep value buy: P/E under 3x, 50%+ FCF yield, insider buying and rebound setup.

121. ❖Aug 24, 8:35 AMnewsvia finnhub

     These S&P500 stocks are moving in today's pre-market session

     Get insights into the top gainers and losers in the S&P500 index of Monday's pre-market session.

122. ❖Aug 24, 7:00 AMnewsvia finnhub

     President and CEO Of Insulet Purchased $162K In Stock

     Disclosed in the latest SEC filing, a significant insider purchase on August 24, involves Ashley McEvoy, President and CEO at Insulet (NASDAQ:PODD). What Happened: McEvoy made a significant move by purchasing 1,100

123. ▢Aug 23, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 11 @ $146.23

124. ❖Aug 5, 8:35 AMnewsvia finnhub

     Wondering what's happening in today's S&P500 pre-market session?

     As we await the opening of the US market on Wednesday, let's delve into the pre-market session and discover the S&P500 top gainers and losers shaping the early market sentiment.

125. ❖Aug 5, 7:18 AMnewsvia finnhub

     Insulet’s (NASDAQ:PODD) Q2 CY2026 Sales Top Estimates But Stock Drops

     Insulin delivery company Insulet Corporation (NASDAQ:PODD) announced better-than-expected revenue in Q2 CY2026, with sales up 23.5% year on year to $801.7 million. On the other hand, next quarter’s revenue guidance of $833.4 million was less impressive, coming in 1.6% below analysts’ estimates. Its non-GAAP profit of $1.66 per share was 14.3% above analysts’ consensus estimates.

126. ❖Aug 5, 7:00 AMnewsvia finnhub

     Insulet Reports Second Quarter 2026 Results

     ACTON, Mass., August 05, 2026--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended June 30, 2026.

127. ▣Aug 4, 8:00 PMjournalstop

     Agent 5 — Dip Buyer (Evolving) closed long 19 @ $131.21 (-$300.34)

     intraday stop sweep

128. ❖Jul 29, 7:30 AMnewsvia finnhub

     GE HealthCare Technologies (GEHC) Beats Q2 Earnings and Revenue Estimates

     GE HealthCare (GEHC) delivered earnings and revenue surprises of +8.65% and +0.41%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

129. ❖Jul 22, 8:43 AMnewsvia finnhub

     Insulet's Q2 2026 Earnings: What to Expect

     Insulet will release its second-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

130. ▣Jul 20, 8:00 PMjournaltarget

     Agent 4 — Dip Buyer (Frozen) closed long 7 @ $167.37 (+$198.80)

     Target hit: close $167.37 ≥ target $164.66

131. ❖Jul 20, 12:43 PMnewsvia finnhub

     Goldman Flags 3 AI-Resistant Investment Themes to Watch

     Last week’s chip-led selloff showcased just how quickly sentiment on AI can shift and drive a rotation out of tech stocks. Goldman Sachs outlined three investment themes to play for investors worried about AI overexposure in their portfolio.

132. ❖Jul 20, 8:15 AMnewsvia finnhub

     1 Healthcare Stock to Target This Week and 2 We Brush Off

     Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 13.3% over the past six months, topping the S&P 500 by 2.5 percentage points.

133. ❖Jul 16, 8:35 AMnewsvia finnhub

     Carlsmed Announces Aprevo Bi-Lateral Posterior Lumbar Interbody Fusion Procedure

134. ❖Jul 16, 4:30 AMnewsvia finnhub

     Insulet Corp (NASDAQ:PODD): A Quality Affordable Growth Stock With Strong Earnings Momentum

     Insulet Corp (PODD) fits the Affordable Growth strategy with strong earnings and revenue momentum, neutral valuation, and high profitability—offering compound growth potential without overpaying for the stock.

135. ❖Jul 15, 9:56 AMnewsvia finnhub

     Artisan Mid Cap Fund Q2 2026 Performance Review

     Artisan Mid Cap Fund portfolio generated strong absolute returns and outpaced the Russell Midcap® Growth Index. Read more here.

136. ❖Jul 15, 6:53 AMnewsvia finnhub

     3 Quality Compounders on Our Buy List

     Quality compounders are well-oiled machines. Their competitive advantages allow them to make profits consistently and reinvest them into projects that generate even more profits, creating a virtuous cycle of returns.

137. ❖Jul 15, 1:05 AMnewsvia finnhub

     The Ithaka Group Q2 2026 Portfolio Review

     AMD stock price exploded higher in the quarter as the evolution of the LLM market has led us to agentic AI workloads.

138. ❖Jul 14, 3:00 AMnewsvia finnhub

     Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss

     ACTON, Mass., July 14, 2026--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced a global partnership with Calm, a leading consumer mental health company, to provide emotional well-being resources for people living with diabetes, their caregivers, and healthcare professionals. The partnership launches Calm’s first-ever integrated content partnership and collection with a MedTech co

139. ❖Jul 14, 12:30 AMnewsvia finnhub

     Global Blood Glucose Monitoring System Market Size to Reach USD 39.4 Billion by 2035 | Growing at 8.9% CAGR | Industry Trends, Market Share & Forecast – Custom Market Insights

     [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Blood Glucose Monitoring System Market size & share revenue was valued at approximately USD 16.8 Billion in 2025 and is expected to reach USD 18.3 Billion in 2026 and is expected to reach around USD 39.4 Billion by 2035, at a CAGR of 8.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Insulet Corporati

140. ❖Jul 13, 11:26 PMnewsvia finnhub

     Insulet Corporation Partners With Calm To Provide Free Mindfulness Resources Addressing Anxiety And Burnout Among People Living With Diabetes

     The partnership introduces The Mind in Range Collection, a set of tailored mindfulness resources available at no cost to the diabetes community, including a meditation series, a breathing exercise, and a new Calm Sleep

141. ❖Jul 13, 9:49 AMnewsvia finnhub

     Insulet Corporation (PODD) Fell Along with Broad Medtech Sector

     ClearBridge Investments, a global equity manager, recently published second-quarter 2026 commentary for its “SMID Cap Growth Strategy”. A copy can be downloaded here. Small and mid-cap (SMID) growth equities experienced the strongest quarter in recent memory, with the Russell 2500 Growth Index rising 24.0%, driven by enthusiasm for AI infrastructure and higher-beta momentum stocks. The […]

142. ❖Jul 13, 8:30 AMnewsvia finnhub

     Here's How Much You'd Have If You Invested $1000 in Insulet a Decade Ago

     Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

143. ❖Jul 13, 8:23 AMnewsvia finnhub

     Truist Securities Maintains Buy on Insulet, Lowers Price Target to $210

     Truist Securities analyst Richard Newitter maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $219 to $210.

144. ❖Jul 13, 6:20 AMnewsvia finnhub

     RBC Capital Maintains Outperform on Insulet, Lowers Price Target to $245

     RBC Capital analyst Shagun Singh maintains Insulet (NASDAQ:PODD) with a Outperform and lowers the price target from $280 to $245.

145. ❖Jul 10, 8:08 AMnewsvia finnhub

     DXCM Grew. The Stock Did Not. Someone Is Wrong

     The company’s business grew at a healthy clip, yet its stock price went sideways and its valuation fell. Something has to give.

146. ❖Jul 10, 5:15 AMnewsvia finnhub

     Stifel Maintains Buy on Insulet, Lowers Price Target to $225

     Stifel analyst Jonathan Block maintains Insulet (NASDAQ:PODD) with a Buy and lowers the price target from $250 to $225.

147. ❖Jul 10, 3:12 AMnewsvia finnhub

     Insulet (PODD) Stock Still Trades At A Premium As Shares Fell 47%

     Insulet stock has fallen sharply over the past year, yet the valuation checks still lean toward the shares being on the expensive side rather than a clear bargain. Insulet is down 46.8% over the past year, which means anyone looking at the stock today is doing so after a significant reset in the share price. On the one hand, growth expectations around the Omnipod franchise may support the current price. On the other hand, class action lawsuits and an FDA Class I recall highlight product and...

148. ❖Jul 10, 2:14 AMnewsvia finnhub

     Insulet (PODD) Launches Omnipod 5 In Spain, Is The Stock Cheap?

     Insulet (PODD) has drawn fresh attention after announcing the commercial launch of its Omnipod 5 Automated Insulin Delivery System and Omnipod Discover data platform in Spain, adding another European market to its footprint. See our latest analysis for Insulet. Despite the positive headlines from Spain, Insulet’s share price return over the past year has declined 46.78% on a total shareholder return basis, with shorter term share price momentum also weaker. This suggests investors are still...

149. ❖Jul 8, 5:38 PMnewsvia finnhub

     Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM

     By Karen Roman Glucotrack, Inc. (Nasdaq: GCTK) said the US Patent and Trademark Office issued a Notice of Allowance for a patent application which expands the intellectual property protecting the company’s continuous blood glucose monitoring (CBGM) platform as it moves towards commercialization. This adds to the company’s three CBGM patents issued in 2025 and includes […] The post Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM appeared first on ExecEdge.

150. ❖Jul 8, 10:50 AMnewsvia finnhub

     Is Insulet Corporation (PODD) Stock Still a Diabetes Device Growth Opportunity After Analyst Target Cut?

     We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Insulet Corporation (NASDAQ:PODD) is one of the best healthcare stocks on our list. TheFly reported on July 6 that Evercore ISI reduced its price target on PODD to $180 from $200 while maintaining an Outperform rating on the shares. The adjustment […]

151. ❖Jul 8, 10:21 AMnewsvia finnhub

     Insulet Broadens Omnipod 5 Presence With Commercial Launch in Spain

     PODD expands Omnipod 5 to Spain, marking its 20th country launch and adding Omnipod Discover to strengthen digital diabetes care.

152. ❖Jul 8, 7:36 AMnewsvia finnhub

     Citigroup Maintains Neutral on Insulet, Raises Price Target to $172

     Citigroup analyst Joanne Wuensch maintains Insulet (NASDAQ:PODD) with a Neutral and raises the price target from $165 to $172.

153. ❖Jul 7, 12:24 PMnewsvia finnhub

     Is it Prudent to Retain Insulet Stock in Your Portfolio for Now?

     PODD's Omnipod 5 momentum and global growth support its outlook, but competitive pressure and macro costs may test its margin expansion plans.

154. ❖Jul 7, 12:10 PMnewsvia finnhub

     Why Insulet (PODD) Could Beat Earnings Estimates Again

     Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

155. ❖Jul 7, 9:22 AMnewsvia finnhub

     How To Target A 10% Yield While Catching The BSX Stock Knife?

     Generate an immediate income that you keep regardless, plus the opportunity to buy the stock cheaper should its price fall far enough.

156. ❖Jul 7, 7:10 AMnewsvia finnhub

     Insulet launches Omnipod 5 in Spain

     A high rate of continuous glucose monitor adoption and low level of automated insulin delivery system penetration make Spain an attractive market for Insulet.

157. ❖Jul 6, 3:45 PMnewsvia finnhub

     Insulet (PODD): Deutsche Bank Initiates Coverage With a Buy and a $190 Target

     Insulet Corporation (NASDAQ:PODD) is one of the best stocks to invest in according to Two Sigma Advisors with huge upside potential. On June 23, Deutsche Bank analyst Kieran Ryan initiated coverage on Insulet Corporation (NASDAQ:PODD) with a Buy rating and a price target of $190. Ryan views Insulet as the dominant player in the tubeless […]

158. ❖Jul 6, 10:35 AMnewsvia finnhub

     Which S&P500 stocks are gapping on Monday?

     Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Monday and stay ahead of the market trends.

159. ❖Jul 6, 9:36 AMnewsvia finnhub

     FDA Classifies Insulet Omnipod Recall as Serious After Injury Reports

     FDA classified Insulet's Omnipod pod recall as Class I after reports of insulin under-delivery linked to 24 serious injuries.

160. ▢Jun 30, 8:00 PMjournal

     Agent 7 — Day Trader opened long 18 @ $158.10

161. ▣Jun 30, 8:00 PMjournaltime_stop

     Agent 7 — Day Trader closed long 18 @ $159.59 (+$26.91)

     EOD forced close — day trader never carries overnight

162. ▣Jun 21, 8:00 PMjournalstop

     Agent 8 — Dip Buyer (Peer-Aware) closed long 6 @ $139.54 (-$50.19)

     intraday stop sweep

163. ▢Jun 21, 8:00 PMjournal

     Agent 4 — Dip Buyer (Frozen) opened long 7 @ $138.97

164. ▢May 31, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 19 @ $147.02

165. ▢May 18, 8:00 PMjournal

     Agent 8 — Dip Buyer (Peer-Aware) opened long 6 @ $147.91